查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918108

亨廷頓舞蹈症治療市場－2026-2031年預測

Huntington's Disease Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計亨廷頓舞蹈症治療市場將從 2025 年的 9.35 億美元成長到 2031 年的 21.29 億美元，複合年成長率為 14.7%。

亨廷頓舞蹈症治療市場預計將穩定成長，這主要得益於針對這種複雜神經退化性疾病的研發活動顯著活性化。市場格局的特點是從對症治療轉向疾病修正治療，大量科學研究和資金資源正投入先進治療方法中。

市場擴張的關鍵驅動力在於強大且不斷成長的在臨床實驗藥物管線。臨床試驗格局正在快速變化，湧現出多種新型治療方法。這些方法包括針對特定病理路徑（例如異常補體系統活性）的單株抗體，以及目前處於中後期臨床試驗階段的先進細胞療法，例如幹細胞療法。臨床研究的蓬勃發展反映了各方為識別和檢驗可能改變疾病進展的治療方法而做出的共同努力。

同時，基因療法已成為一個極具前景且發展迅速的領域。多個基因療法候選藥物正處於臨床開發階段，其作用機制主要集中在抑制亨丁頓舞蹈症突變基因的表達。美國FDA的簡審類等項目正在加速這些創新治療方法的法規核准流程，旨在加速研發和審查進程。這些計畫從早期試驗進入後期研究，標誌著治療產品線已日趨成熟，並成為市場的重要成長動力。

該疾病日益普遍，加之人們對超越對症治療的先進治療方法的需求不斷成長，迫切需要有效的治療方法。這種需求是推動製藥和生技公司投資高風險、高回報研發的根本動力。顯然，研發重點在於開發能夠改變疾病根本病理的干涉措施，而這正是目前最大的未滿足需求，也是最大的市場機會。

北美地區預計將成為關鍵市場，這得益於其高疾病負擔、完善且資金充足的臨床研究基礎設施以及積極的法規環境。該地區是活躍的研發中心，許多成熟的製藥和生物技術公司正在進行大量的臨床試驗。這種科學研究和商業性活動的集中度正在鞏固北美作為全球市場成長主要驅動力的地位。

預計亞太地區在預測期內也將呈現強勁成長。這一成長預計將受到各國主導為改善公民健康和加強醫療基礎設施而不斷加大投入的推動。然而，該地區的市場成長可能會受到競爭激烈的學名藥市場及其相關專利挑戰的限制，這可能會影響品牌藥的商業策略。

總而言之，亨廷頓舞蹈症治療市場正經歷著以科學創新和向緩解疾病治療方法策略轉型為特徵的動態變革時期。隨著基因療法、單株抗體和幹細胞療法在臨床試驗中不斷推進，有利的法規結構和日益成長的投資為市場擴張創造了有利環境。專注於開發治療方法，是塑造市場未來發展軌跡及其滿足重大未滿足需求潛力的核心範式。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

第5章 亨廷頓舞蹈症治療市場（依類型分類）

  • 介紹
  • 藥物治療
    • Tetrabenazine
    • Tetrabenazine
    • 其他
  • 治療
    • 物理治療
    • 語言治療
    • 疾病修正治療

6. 亨廷頓舞蹈症治療市場（依給藥途徑分類）

  • 介紹
  • 注射
  • 口服

7. 亨廷頓舞蹈症治療市場（以最終用戶分類）

  • 介紹
  • 醫院
  • 專科診所
  • 其他

8. 各地區亨廷頓舞蹈症治療市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Teva Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc
  • Neurocrine Biosciences, Inc.
  • Prilenia Therapeutics
  • Novartis AG
  • Lupin Limited
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd
  • Atalanta Therapeutics
  • F. Hoffmann-La Roche AG

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615578

Huntington's Disease Treatment Market is expected to grow at a 14.7% CAGR, achieving USD 2.129 billion in 2031 from USD 0.935 billion in 2025.

The Huntington's disease treatment market is positioned for steady growth, driven by a marked intensification in research and development activities aimed at addressing this complex neurodegenerative disorder. The market landscape is characterized by a shift from symptomatic management toward the pursuit of disease-modifying therapies, with significant scientific and financial resources being channeled into advanced therapeutic modalities.

A primary catalyst for market expansion is the robust and expanding pipeline of investigational treatments. The clinical trial landscape is rapidly evolving, featuring a diverse array of novel therapeutic approaches. These include monoclonal antibodies designed to target specific pathological pathways, such as aberrant complement system activity, and advanced cell-based interventions like stem cell therapies currently in mid-to-late-stage clinical studies. This proliferation of clinical research reflects a concerted effort to identify and validate treatments that can alter the disease's progression.

Concurrently, gene therapy has emerged as a particularly promising and rapidly advancing segment. Multiple gene therapy candidates are progressing through clinical development, with mechanisms of action focused on silencing the expression of the mutant huntingtin gene. The regulatory pathway for these innovative treatments is being facilitated by designations such as the U.S. FDA's Fast Track, which aims to accelerate the development and review process. The progression of these programs from early-stage trials toward later-phase studies underscores a significant maturation in the therapeutic pipeline and represents a substantial growth vector for the market.

The increasing prevalence of the disease, coupled with a growing demand for advanced therapeutic options beyond symptomatic care, is creating a pressing need for effective treatments. This demand is a fundamental driver, incentivizing pharmaceutical and biotechnology companies to invest in high-risk, high-reward research endeavors. The focus is squarely on developing interventions that can modify the underlying disease pathology, a area where the highest unmet medical need and, consequently, the greatest market opportunity reside.

Geographically, North America is anticipated to be a significant marketplace, a status attributed to its high disease burden, well-established and well-funded clinical research infrastructure, and proactive regulatory environment. The region is a hub for active research and development, with numerous clinical trials initiated by both established pharmaceutical firms and biotechnology companies. This concentration of scientific and commercial activity solidifies North America's role as a primary driver of global market growth.

The Asia-Pacific region is also predicted to exhibit robust growth during the forecast period. This expansion is expected to be fueled by increasing government initiatives aimed at improving population health and enhancing healthcare infrastructure. However, market growth in this region may be tempered by a competitive generic drug landscape and associated patent challenges, which can influence the commercial strategy for branded therapeutics.

In summary, the Huntington's disease treatment market is in a dynamic state of transition, defined by scientific innovation and a strategic pivot towards disease-modifying interventions. The advancement of gene therapies, monoclonal antibodies, and stem cell treatments through clinical trials, supported by a conducive regulatory framework and growing investment, is creating a fertile environment for market expansion. The focus on developing therapies that can fundamentally alter the disease course, rather than merely alleviate symptoms, represents the central paradigm shaping the market's future trajectory and its potential to address a significant unmet medical need.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Huntington's Disease Treatment Market Segmentation:

  • By Type
  • Medication
  • Tetrabenazine
  • Deutetrabenazine
  • Others
  • Therapy
  • Physical Therapy
  • Speech Therapy
  • Disease Modifying Therapy
  • By Route of Administration
  • Injectable
  • Oral
  • By End-User
  • Hospitals
  • Specialty Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. HUNTINGTON'S DISEASE TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Medication
    • 5.2.1. Tetrabenazine
    • 5.2.2. Deutetrabenazine
    • 5.2.3. Others
  • 5.3. Therapy
    • 5.3.1. Physical Therapy
    • 5.3.2. Speech Therapy
    • 5.3.3. Disease Modifying Therapy

6. HUNTINGTON'S DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Injectable
  • 6.3. Oral

7. HUNTINGTON'S DISEASE TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Clinics
  • 7.4. Others

8. HUNTINGTON'S DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Teva Pharmaceutical Industries Ltd.
  • 10.2. H. Lundbeck A/S
  • 10.3. Bausch Health Companies Inc
  • 10.4. Neurocrine Biosciences, Inc.
  • 10.5. Prilenia Therapeutics
  • 10.6. Novartis AG
  • 10.7. Lupin Limited
  • 10.8. Hikma Pharmaceuticals PLC
  • 10.9. Dr. Reddy's Laboratories Ltd
  • 10.10. Atalanta Therapeutics
  • 10.11. F. Hoffmann-La Roche AG

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations